Brace yourselves, Ozempic and Zepound. Eli Lilly just released a jaw-dropping sneak peek from the final phases of testing for ...

Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...

The investment narrative surrounding Novo Nordisk is undergoing a significant shift. After years of soaring expectations fueled by its obesity and diabetes t ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

As physicians across specialties encounter increasing patient interest in GLP-1 receptor agonists, it is important for them ...

Though it hasn't even wrapped up clinical trials, the weight loss drug retatrutide already has a cult following.

These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Retatrutide, a new experimental weight-loss drug, targets three hormones and shows promising results far beyond current ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...